Application and Challenges of Chimeric Antigen Receptor T Cell Therapy in Systemic Rheumatic Diseases and Autoimmune Disorders - PubMed
5 hours ago
- #Precision immunology
- #CAR-T therapy
- #Autoimmune diseases
- CAR-T cell therapy, originally for hematologic cancers, shows transformative potential for systemic rheumatic and autoimmune diseases.
- It works by depleting autoreactive B cells and enabling antigen-naïve immune reconstitution, leading to drug-free remission in early trials.
- Clinical and serological responses can last 2-5 years without long-term immunosuppression, but challenges include complex manufacturing and limited tissue penetration.
- Other unmet needs are antigen escape, immunological sequelae, and a lack of predictive biomarkers for patient selection.
- Emerging strategies involve universal or in vivo-generated CAR-T cells, multitargeted designs, organ-homing engineering, and combinations with tolerance-enhancing agents.
- Multiomics integration (e.g., single-cell transcriptomics, spatial mapping) is highlighted for patient stratification and relapse prediction in precision immunotherapy.